SELECT COUNTRY
VIEW ALL
AFRICA
AMERICAS
ASIA
EUROPE
OCEANIA
ALGERIA
ANGOLA
ARGENTINA
AUSTRALIA
AZERBAIJAN
BAHREIN
BELGIUM
BENIN
BOLIVIA
BOTSWANA
BRAZIL
BRUNEI
BURKINA FASO
CAMEROON
CANADA
CENTRAL AFRICAN REPUBLIC
CHAD
CHILE
CHINA
COLOMBIA
COTE D’IVOIRE
CZECH REPUBLIC
DOMINICAN REPUBLIC
DRC
ECUADOR
EGYPT
ETHIOPIA
FINLAND
FRANCE
GABON
GHANA
GREENLAND
GUINEA
HUNGARY
ICELAND
INDIA
INDONESIA
IRAN
IRAQ
ITALY
KAZAKHSTAN
KENYA
KUWAIT
LESOTHO
LIBERIA
MADAGASCAR
MALAWI
MALAYSIA
MALI
MAURITANIE
MEXICO
MONGOLIA
MOROCCO
MOZAMBIQUE
NAMIBIA
NETHERLANDS
NICARAGUA
NIGER
NIGERIA
NORWAY
PANAMA
PAPUA NEW GUINEA
PERU
PHILIPPINES
POLAND
QATAR
REPUBLIC OF CONGO
RUSSIA
RWANDA
SENEGAL
SIERRA LEONA
SINGAPORE
SLOVENIA
SOMALI
SOUTH AFRICA
SOUTH KOREA
SPAIN
SUDAN
SWEDEN
TAIWAN
TANZANIA
THAILAND
TOGO
TRINDAD & TOBAGO
TURKEY
TURKMENISTAN
UAE
UGANDA
UKRAINE
UNITED KINGDOM
UNITED STATES
VENEZUELA
VIETNAM
ZAMBIA
ZIMBABWE
ZIMBABWE: LATEST INTERVIEWS MORE INTERVIEWS
Tembo Power is developing hydropower projects across Africa with a focus on DRC.
Prospect Resources speaks to GBR about its Arcadia lithium mine in Zimbabwe.
Caledonia Mining Corporation speaks about its gold mining activities in Zimbabwe.
Micromine is privately owned Australian software company with offices all around the world.
ZIMBABWE: LATEST ARTICLES
The Geographic Spread of Africa’s Mining Investors
April 26, 2019
International investors demonstrate reinvigorated appetite for Africa’s mining prospects – from traditional partners like the Australians to a growing Chinese and Russian presence.
The Delicate Balancing Act of Developing ‘Vogue Minerals’ Projects
February 05, 2019
Expert Opinion Article contributed by SRK Consulting’s global team of consultants.
ZIMBABWE: RECENTLY RELEASED PUBLICATIONS
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
